Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumat... by Peterfy, C, Dicarlo, J, Emery, P, Genovese, MC, Keystone, EC, Taylor, PC, Schlichting, DE, Beattie, SD, Luchi, M, Macias, W

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirhe... by Genovese, M, Keystone, E, Taylor, P, Drescher, E, Berclaz, P, Lee, C, Schlichting, D, Beattie, S, Fidelus-Gort, R, Luchi, M, Macias, W

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS by Taylor, P, Genovese, M, Keystone, E, Drescher, E, Berclaz, P, Lee, C, Fidelus-Gort, R, Schlichting, D, Beattie, S, Luchi, M, Macias, W

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. by Keystone, E, Taylor, P, Drescher, E, Schlichting, D, Beattie, S, Berclaz, P, Lee, C, Fidelus-Gort, R, Luchi, M, Rooney, T, Macias, W, Genovese, M

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modify... by Peterfy, C, Emery, P, Genovese, M, Keystone, E, Taylor, P, Berclaz, P, DiCarlo, J, Lee, C, Schlichting, D, Beattie, S, Luchi, M, Macias, W